Stocks and InvestingStocks and Investing
Tue, March 30, 2021
Mon, March 29, 2021
Fri, March 26, 2021
Thu, March 25, 2021
Wed, March 24, 2021
Tue, March 23, 2021

Matthew Harrison Maintained (AKRO) at Buy with Decreased Target to $63 on, Mar 23rd, 2021


Published on 2024-10-27 16:01:01 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Akero Therapeutics, Inc." (AKRO) at Buy with Decreased Target from $70 to $63 on, Mar 23rd, 2021.

Matthew has made no other calls on AKRO in the last 4 months.



There are 3 other peers that have a rating on AKRO. Out of the 3 peers that are also analyzing AKRO, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $46 on, Thursday, March 18th, 2021
  • Michael Morabito of "Chardan Capital" Maintained at Strong Buy with Increased Target to $81 on, Wednesday, March 17th, 2021
  • Etzer Darout of "Guggenheim" Initiated at Strong Buy and Held Target at $54 on, Friday, February 26th, 2021